We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
EYDENZELT Celltrion Healthcare Australia Pty Ltd
Product name
EYDENZELT
Accepted date
Jul-2025
Active ingredients
Aflibercept
Proposed indication
Eydenzelt (aflibercept) is proposed to be used in adults to treat eye conditions that cause vision problems, including:
-wet age-related macular degeneration (wet AMD) which affects the retina and leads to vision loss.
-macular swelling from central retinal vein blockage (CRVO), when the main vein in the retina is blocked, causing fluid buildup.
-macular swelling from branch retinal vein blockage (BRVO), which affects smaller veins.
-diabetic macular oedema (DME), swelling in the retina due to diabetes.
-Myopic choroidal neovascularisation (myopic CNV), abnormal blood vessel growth in people with severe short-sightedness.
-wet age-related macular degeneration (wet AMD) which affects the retina and leads to vision loss.
-macular swelling from central retinal vein blockage (CRVO), when the main vein in the retina is blocked, causing fluid buildup.
-macular swelling from branch retinal vein blockage (BRVO), which affects smaller veins.
-diabetic macular oedema (DME), swelling in the retina due to diabetes.
-Myopic choroidal neovascularisation (myopic CNV), abnormal blood vessel growth in people with severe short-sightedness.
Application type
C (new indication)
Publication date
Jul-2025